Abstract
The glucocorticoids are effective anti-inflammatory agents but their use may be limited by systemic side effects. AL-438 and prednisolone inhibit binding to glucocorticoid and mineralcorticoid receptors with similar potency. In rat models of acute and chronic inflammation, AL-438 was effective but less potent than prednisolone. In fasted overnight rats, prednisolone was hyperglycaemic but AL-438 was not. Prednisolone also inhibited bone formation in rats, whereas AL-438 did not. The differing profile of AL-438 relative to prednisolone may be due to altered interactions between the receptor and selected co-activators. AL-438 may have lesser side effects than prednisolone.